Targeted CML therapy: controlling drug resistance, seeking cure
- 28 February 2006
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Genetics & Development
- Vol. 16 (1), 92-99
- https://doi.org/10.1016/j.gde.2005.11.002
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Leukaemia stem cells and the evolution of cancer-stem-cell researchNature Reviews Cancer, 2005
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Punish the parent not the progenyBlood, 2005
- Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemiaCancer Immunology, Immunotherapy, 2004
- The biology of CML blast crisisBlood, 2004
- The BCR-ABL Story: Bench to Bedside and BackAnnual Review of Immunology, 2004
- Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylateBlood, 2004
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- The molecular biology of chronic myeloid leukemiaBlood, 2000